Clinical Trial: Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus

Study Status: Terminated
Recruit Status: Unknown status
Study Type: Observational

Official Title: Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus

Brief Summary:

This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls.

Regardless the treatment status, we collect the same neuroendocrine-immune data on the participants after 2 months.

Detailed Summary:

This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls.

Regardless the treatment status, we collect the same neuroendocrine-immune on the participants (patients and controls) after 2 months. Thus, our study does not control treatment. Patients take treatment in consultation with their physician. Some of them even decide not to take any medications. At the 2nd visit, we do ask them about the the medications they are taking if any.

Sponsor: University of Pittsburgh

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of Pittsburgh

Dates:
Date Received: September 13, 2005
Date Started: August 2003
Date Completion: June 2014
Last Updated: February 16, 2011
Last Verified: February 2011